Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 555 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... December 5, 2023 Study Shows Supplements Increase Risk of Relapse and Death in Breast... January 7, 2020 Overall Survival Significantly Longer with Darolutamide in Non-metastatic CRPC September 14, 2020 Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... July 29, 2025 Load more HOT NEWS Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... How will new cancer medicines be approved in the future? EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer...
